SAN FRANCISCO & SUNNYVALE, Calif.--(BUSINESS WIRE)--Universal Brain, a neurotechnology company pioneering objective brain-function measurement for mental health, today announced the first clinical deployment of its U.S. Food and Drug Administration (FDA)-cleared UB ERP System at Acacia Clinics, a Silicon Valley psychiatry practice specializing in precision neuromodulation and advanced treatments for depression, anxiety, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). The deployment marks an important milestone in bringing rapid, objective measurement of brain function into routine psychiatric care following the system’s FDA 510(k) clearance in June 2026.
Acacia Clinics, which specializes in treatment-resistant depression and related conditions and offers advanced interventions including functional magnetic resonance imaging (fMRI)-guided transcranial magnetic stimulation (TMS), accelerated TMS protocols including HOPE-TMS®, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) and SPRAVATO® (esketamine), will be the first clinical site to deploy the UB ERP System following FDA clearance. The initial three-month pilot will evaluate how rapid brain-function assessments can be incorporated into existing clinical workflows and provide clinicians with additional objective information alongside established psychiatric evaluations.
Universal Brain’s UB ERP System combines its proprietary UB Cap, a dry-electrode electroencephalography (EEG) headset, with software that measures and analyzes event-related potentials (ERPs), the brain’s electrical responses to specific stimuli. By eliminating the need for conductive gels and streamlining data acquisition and analysis, the system enables clinicians to complete an assessment, from EEG cap setup to analyzed results, allowing for rapid brain function measurement.